704 related articles for article (PubMed ID: 26148346)
1. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
2. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis.
Lei L; Zhao C; Qin F; He ZY; Wang X; Zhong XN
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):14-22. PubMed ID: 26750756
[TBL] [Abstract][Full Text] [Related]
3. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
[TBL] [Abstract][Full Text] [Related]
4. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
[TBL] [Abstract][Full Text] [Related]
5. Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis.
Lei L; He ZY; Zhao C; Sun XJ; Zhong XN
Int J Rheum Dis; 2016 Apr; 19(4):392-404. PubMed ID: 25545680
[TBL] [Abstract][Full Text] [Related]
6. Effects of thalidomide on Th17, Treg cells and TGF-β1/Smad3 pathway in a mouse model of systemic sclerosis.
Lu Y; Zhao C; Lei L; Tao Z; Zheng L; Wen J; Li X
Int J Rheum Dis; 2020 Mar; 23(3):406-419. PubMed ID: 31840939
[TBL] [Abstract][Full Text] [Related]
7. In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis.
Fineschi S; Bongiovanni M; Donati Y; Djaafar S; Naso F; Goffin L; Argiroffo CB; Pache JC; Dayer JM; Ferrari-Lacraz S; Chizzolini C
Am J Respir Cell Mol Biol; 2008 Oct; 39(4):458-65. PubMed ID: 18458239
[TBL] [Abstract][Full Text] [Related]
8. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
9. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
Hasegawa M; Matsushita Y; Horikawa M; Higashi K; Tomigahara Y; Kaneko H; Shirasaki F; Fujimoto M; Takehara K; Sato S
Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032
[TBL] [Abstract][Full Text] [Related]
10. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.
Leonhardt F; Zirlik K; Buchner M; Prinz G; Hechinger AK; Gerlach UV; Fisch P; Schmitt-Gräff A; Reichardt W; Zeiser R
Leukemia; 2012 Jul; 26(7):1617-29. PubMed ID: 22301676
[TBL] [Abstract][Full Text] [Related]
11. The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis.
Can G; Ayvaz S; Can H; Demirtas S; Aksit H; Yilmaz B; Korkmaz U; Kurt M; Karaca T
J Crohns Colitis; 2015 Oct; 9(10):907-17. PubMed ID: 26116555
[TBL] [Abstract][Full Text] [Related]
12. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
Ohashi T; Yamamoto T
Exp Dermatol; 2015 Sep; 24(9):698-702. PubMed ID: 25959255
[TBL] [Abstract][Full Text] [Related]
13. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Hilgendorf I; Eisele S; Remer I; Schmitz J; Zeschky K; Colberg C; Stachon P; Wolf D; Willecke F; Buchner M; Zirlik K; Ortiz-Rodriguez A; Lozhkin A; Hoppe N; von zur Muhlen C; zur Hausen A; Bode C; Zirlik A
Arterioscler Thromb Vasc Biol; 2011 Sep; 31(9):1991-9. PubMed ID: 21700926
[TBL] [Abstract][Full Text] [Related]
14. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.
McAdoo SP; Reynolds J; Bhangal G; Smith J; McDaid JP; Tanna A; Jackson WD; Masuda ES; Cook HT; Pusey CD; Tam FW
J Am Soc Nephrol; 2014 Oct; 25(10):2291-302. PubMed ID: 24700868
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness.
Matsubara S; Li G; Takeda K; Loader JE; Pine P; Masuda ES; Miyahara N; Miyahara S; Lucas JJ; Dakhama A; Gelfand EW
Am J Respir Crit Care Med; 2006 Jan; 173(1):56-63. PubMed ID: 16192454
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling.
Chen CW; Beyer C; Liu J; Maier C; Li C; Trinh-Minh T; Xu X; Cole SH; Hsieh MH; Ng N; Althage A; Meeusen S; Pan S; Svensson EC; Seidel HM; Schett G; Gergely P; Harris JL; Distler JH
Ann Rheum Dis; 2017 Apr; 76(4):773-778. PubMed ID: 28153829
[TBL] [Abstract][Full Text] [Related]
17. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies.
Lhermusier T; van Rottem J; Garcia C; Xuereb JM; Ragab A; Martin V; Gratacap MP; Sié P; Payrastre B
J Thromb Haemost; 2011 Oct; 9(10):2067-76. PubMed ID: 21848694
[TBL] [Abstract][Full Text] [Related]
18. Effects of a spleen tyrosine kinase inhibitor on progression of the lupus nephritis in mice.
Kitai M; Fukuda N; Ueno T; Endo M; Maruyama T; Abe M; Okada K; Soma M; Matsumoto K
J Pharmacol Sci; 2017 May; 134(1):29-36. PubMed ID: 28479222
[TBL] [Abstract][Full Text] [Related]
19. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
20. The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells.
Platt AM; Benson RA; McQueenie R; Butcher JP; Braddock M; Brewer JM; McInnes IB; Garside P
Rheumatology (Oxford); 2015 Jan; 54(1):169-77. PubMed ID: 25065010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
